Monthly Archives: March 2023

Government Funding For Research, 1

Posted on March 30, 2023 by Gerald Barnett

Out in Twitterland, I saw this tweet by Brett Blackham: Arguably, research and development is so important that government should have nothing to do with it. However since 1980 a company or university could get government money to do research … Continue reading →

Posted in Bad Science, Innovation, Sponsored Research | Tagged , | Comments Off on Government Funding For Research, 1

Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in

Posted on March 23, 2023 by Gerald Barnett

The American Prospect has an interesting piece (“A Big Miss on Drug Prices”) on the NIH yet again defying the Bayh-Dole Act and refusing to launch an investigation into whether UCLA and Pfizer have met Bayh-Dole’s standard (35 USC 201(f)) … Continue reading →

Posted in Bayh-Dole | Tagged , , , , | Comments Off on Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in

Inventors would own more, were it not for noncompliant Bayh-Dole practice

Posted on March 10, 2023 by Gerald Barnett

I saw this tweet this morning: I agree Inventors should own more, but institutions were/are the heart of Bayh-Dole that (arguably) enables IP-driven startups… this is bc many/most PI inventions would go into a black hole without tech transfer officer … Continue reading →

Posted in Bayh-Dole, Metrics, Patents, Policy | Tagged , , , | Comments Off on Inventors would own more, were it not for noncompliant Bayh-Dole practice

Why not let’s try, Frank?

Posted on March 9, 2023 by Gerald Barnett

Frank Cullen, writing at the “Council for Innovation Promotion” has posted a hand-wringing response to a letter from members of Congress to the Secretary of Health and Human Services requesting that the government use Bayh-Dole’s march-in provisions to address price … Continue reading →

Posted in Bayh-Dole, Patents, Policy | Tagged , , | Comments Off on Why not let’s try, Frank?

March-in rights, Xtandi, and Bayh-Dole’s patent rights clause

Posted on March 3, 2023 by Gerald Barnett

Senator Bernie Sanders just tweeted about Xtandi, asking patients taking Xtandi to share their stories. The prostate cancer drug Xtandi was invented by taxpayer-funded scientists at UCLA, but now costs Americans nearly $190,000 — or up to six times the … Continue reading →

Posted in Bayh-Dole, high priced drugs | Tagged , , , , | Comments Off on March-in rights, Xtandi, and Bayh-Dole’s patent rights clause